MedTrace Logo

Survival After Blood Transfusion in the French Administrative Regions of Burgundy and Franche-Comté

NCT02852993 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16099

Last updated 2016-08-02

No results posted yet for this study

Summary

Red blood cell transfusion (RBC) is the main symptomatic treatment for severe anemia. RBC transfusion has proven its efficacy regarding mortality and morbidity, but it is not without side effects. The infectious side effects of transfusion are largely considered under control, non-infectious side effects are taking center stage. Seeking explanations for the beneficial and deleterious effects of RBC transfusions is necessary to ensure the safe and optimal use of this precious resource.

The investigators aim to study the impact of donor and RBC characteristics on patient survival.

Conditions

  • Erythrocyte Transfusion for All Conditions

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Dijon

    collaborator OTHER

  • Etablissement Français du Sang

    collaborator OTHER

  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Principal Investigators

  • Maxime Desmarets, MD, PhD · Centre d'Investigation Clinique; CHU Besançon

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02852993 on ClinicalTrials.gov